GlassScriptPhysician profile
Rakesh Grover
NPI 1790836153
$1,564.66
in general payments reported to CMS, 2019-2025
27 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $143 · 2021: $448 · 2022: $99.56 · 2023: $73.86 · 2024: $205 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $228.48 | 2019-2020 | |
| Abbvie INC. | $208.16 | 2019-2025 | |
| Janssen Biotech, INC. | $168.82 | 2025 | Tremfya |
| Trevena, INC. | $167.36 | 2021 | |
| Merck Sharp & Dohme LLC | $160.63 | 2021-2024 | Dificid |
| Medtronic, INC. | $74.40 | 2021-2022 | |
| Smith+Nephew, INC. | $59.83 | 2019-2021 | |
| Acell, INC. | $42.25 | 2020 | |
| Madrigal Pharmaceuticals | $38.94 | 2025 | Rezdiffra |
| Integra Lifesciences Corporation | $38.53 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Genzyme Corporation | $35.25 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.01 | 2024 | Entyvio |
| Glaxosmithkline, LLC. | $27.57 | 2021 | |
| Allergan, INC. | $26.00 | 2020 | |
| Novo Nordisk INC | $25.22 | 2025 | Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $24.33 | 2021 | |
| Aimmune Therapeutics, INC. | $23.37 | 2024 | |
| Ardelyx, INC. | $21.71 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $20.05 | 2022 | |
| Innocoll Pharmaceuticals Limited | $19.29 | 2021 | |
| Intuitive Surgical, INC. | $19.10 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.09 | 2019 | |
| Amarin Pharma, INC. | $18.74 | 2021 | |
| Organogenesis INC. | $18.42 | 2024 | |
| Livanova USA, INC. | $18.36 | 2021 | |
| Baxter Healthcare | $16.01 | 2023 | Seprafilm |
| Kci USA, INC. | $15.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.